Clinical presentation and long-term outcome of 144 patients with microscopic polyangiitis in a monocentric German cohort

Rheumatology (United Kingdom)

Volumn 55, Issue 1, 2016, Pages 71-79

  Schirmer, Jan H ^a   Wright, Marvin N ^b   Vonthein, Reinhard ^b   Herrmann, Kristine ^a,g   Nölle, Bernhard ^c   Both, Marcus ^c   Henes, Frank O ^d   Arlt, Andreas ^e   Gross, Wolfgang L ^f   Schinke, Susanne ^a   Reinhold Keller, Eva ^a   Moosig, Frank ^a   Holle, Julia U ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e Klinikum Bad Bramstedt   (Germany)

^f UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^g UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

ANCA; interstitial lung disease; MPA; Pulmonary fibrosis; vasculitis

Indexed keywords

AZATHIOPRINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; FOLIC ACID; LEFLUNOMIDE; MESNA; METHOTREXATE; MYCOPHENOLATE MOFETIL; PREDNISOLONE; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ANCA ASSOCIATED VASCULITIS; ARTICLE; CARDIOVASCULAR MORTALITY; CLASSIFICATION ALGORITHM; COHORT ANALYSIS; CYSTITIS; DISEASE ASSESSMENT; DISEASE COURSE; DRUG MEGADOSE; END STAGE RENAL DISEASE; EUROPEAN MEDICINES AGENCY; FOLLOW UP; HUMAN; INTERSTITIAL LUNG DISEASE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MICROSCOPIC POLYANGIITIS; MOTOR NEUROPATHY; MYOSITIS; PATIENT REFERRAL; PERIPHERAL NERVOUS SYSTEM; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; RELAPSE; REMISSION; RETROSPECTIVE STUDY; SENSORIMOTOR NEUROPATHY; SENSORY NEUROPATHY; SMALL VESSEL VASCULITIS; TERTIARY CARE CENTER;

EID: 84960121823     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kev286     Document Type: Article

References (43)

1. Jennette JC, Falk RJ, Bacon PA et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013;65:1-11.
2. Mukhtyar C, Flossmann O, Hellmich B et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis 2008;67:1004-10.
3. Lane SE, Watts RA, Shepstone L, Scott DGI. Primary systemic vasculitis: clinical features and mortality. QJM 2005;98:97-111.
4. Corral-Gudino L, Borao-Cengotita-Bengoa M, Del Pino-Montes J, Lerma-Márquez JL. Overall survival, renal survival and relapse in patients with microscopic polyangiitis: a systematic review of current evidence. Rheumatology 2011;50:1414-23.
5. Casian A, Jayne D. Management of alveolar hemorrhage in lung vasculitides. Semin Respir Crit Care Med 2011;32:335-45.
6. Tzelepis GE, Kokosi M, Tzioufas A et al. Prevalence and outcome of pulmonary fibrosis in microscopic polyangiitis. Eur Respir J 2010;36:116-21.
7. Arulkumaran N, Periselneris N, Gaskin G et al. Interstitial lung disease and ANCA-associated vasculitis: a retrospective observational cohort study. Rheumatology 2011;50:2035-43.
8. Reinhold-Keller E, Beuge N, Latza U et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000;43:1021-32.
9. Watts R, Lane S, Hanslik T et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 2007;66:222-7.
10. Holle JU, Gross WL, Latza U et al. Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades. Arthritis Rheum 2011;63:257-66.
11. Hellmich B, Flossmann O, Gross WL et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on antineutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 2007;66:605-17.
12. Luqmani RA, Bacon PA, Moots RJ et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994;87:671-8.
13. de Groot K, Gross WL, Herlyn K, Reinhold-Keller E. Development and validation of a disease extent index for Wegener's granulomatosis. Clin Nephrol 2001;55:31-8.
14. Exley AR, Bacon PA, Luqmani RA et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997;40:371-80.
15. Mukhtyar C, Guillevin L, Cid MC et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009;68:310-7.
16. de Groot K, Harper L, Jayne DRW et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009;150:670-80.
17. Department of Demography, University of California, Berkeley, Berkeley, CA, USA and Data Laboratory, Max Planck Institute for Demographic Research, Rostock, Germany. Human Mortality Database. http://www.mortality. org or http://www.humanmortality.de (19 March, 2014, date last accessed).
18. R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing 2014. http://www. R-project.org/(30 July 2015, date last accessed).
19. Rihova Z, Jancova E, Merta M et al. Long-term outcome of patients with antineutrophil cytoplasmic autoantibodyassociated vasculitis with renal involvement. Kidney Blood Press Res 2005;28:144-52.
20. Westman KW, Bygren PG, Olsson H, Ranstam J, Wieslander J. Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol 1998;9:842-52.
21. Nachman PH, Hogan SL, Jennette JC, Falk RJ. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 19967:33-9.
22. Guillevin L, Durand-Gasselin B, Cevallos R et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 1999;42:421-30.
23. Furuta S, Chaudhry AN, Hamano Y et al. Comparison of phenotype and outcome in microscopic polyangiitis between Europe and Japan. J Rheumatol 2014;41:325-33.
24. Sugiyama K, Sada K, Kurosawa M, Wada J, Makino H. Current status of the treatment of microscopic polyangiitis and granulomatosis with polyangiitis in Japan. Clin Exp Nephrol 2013;17:51-8.
25. Mohammad AJ, Jacobsson LTH, Westman KWA, Sturfelt G, Segelmark M. Incidence and survival rates in Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. Rheumatology 2009;48:1560-5.
26. Kawai H, Banno S, Kikuchi S et al. Retrospective analysis of factors predicting end-stage renal failure or death in patients with microscopic polyangiitis with mainly renal involvement. Clin Exp Nephrol 2014;18:795-802.
27. Little MA, Nightingale P, Verburgh CA et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 2010;69:1036-43.
28. Robson J, Doll H, Suppiah R et al. Damage in the ANCAassociated vasculitides: long-term data from the European Vasculitis Study group (EUVAS) therapeutic trials. Ann Rheum Dis 2015;74:177-84.
29. Huang H, Wang YX, Jiang CG et al. A retrospective study of microscopic polyangiitis patients presenting with pulmonary fibrosis in China. BMC Pulm Med 2014;14:8.
30. Hervier B, Pagnoux C, Agard C et al. Pulmonary fibrosis associated with ANCA-positive vasculitides. Retrospective study of 12 cases and review of the literature. Ann Rheum Dis 2009;68:404-7.
31. Ando Y, Okada F, Matsumoto S, Mori H. Thoracic manifestation of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA)-related disease. CT findings in 51 patients. J Comput Assist Tomogr 2004;28:710-6.
32. Foulon G, Delaval P, Valeyre D et al. ANCA-associated lung fibrosis: analysis of 17 patients. Respir Med 2008;102:1392-8.
33. Tanaka T, Otani K, Egashira R et al. Interstitial pneumonia associated with MPO-ANCA: clinicopathological features of nine patients. Respir Med 2012;106:1765-70.
34. Becker-Merok A, Nossent JC, Ritland N. Fibrosing alveolitis predating microscopic polyangiitis. Scand J Rheumatol 1999;28:254-6.
35. Fernandez Casares M, Gonzalez A, Fielli M et al. Microscopic polyangiitis associated with pulmonary fibrosis. Clin Rheumatol 2015;34:1273-7.
36. Comarmond C, Crestani B, Tazi A et al. Pulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: a series of 49 patients and review of the literature. Medicine 2014;93:340-9.
37. Kostianovsky A, Hauser T, Pagnoux C et al. Alveolar haemorrhage in ANCA-associated vasculitides: 80 patients' features and prognostic factors. Clin Exp Rheumatol 2012;30(1 Suppl 70):S77-82.
38. Suppiah R, Hadden RDM, Batra R et al. Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials. Rheumatology 2011;50:2214-22.
39. Flossmann O, Berden A, de Groot K et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 2011;70:488-94.
40. Hogan SL, Nachman PH, Wilkman AS, Jennette JC, Falk RJ. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996;7:23-32.
41. Cattaneo L, Chierici E, Pavone L et al. Peripheral neuropathy in Wegener's granulomatosis, Churg-Strauss syndrome and microscopic polyangiitis. J Neurol Neurosurg Psychiatry 2007;78:1119-23.
42. Pavone L, Grasselli C, Chierici E et al. Outcome and prognostic factors during the course of primary smallvessel vasculitides. J Rheumatol 2006;33:1299-306.
43. Hattori N, Mori K, Misu K et al. Mortality and morbidity in peripheral neuropathy associated Churg-Strauss syndrome and microscopic polyangiitis. J Rheumatol 2002;29:1408-14.